

## **ZP General Partner 3 ApS**

---

# **Annual report 2019/2020**

For the period 9 December 2019 – 31 December 2020

## **ZP General Partner 3 ApS**

Sydmarken 11  
DK-2860 Søborg

**Central Business Registration No. 41023422**

The Annual General Meeting adopted the annual report on 30 June 2021.

### **Chairman of the General Meeting**

DocuSigned by:

*Hans-Christian Lund*

A8E08C1E9A5244B...

---

Hans-Christian Lund  
Legal Counsel

## **ZP General Partner 3 ApS**

---

### **Contents**

	<b>Page</b>
Entity details	3
Statement by Management on the annual report	4
Independent auditor's report	5
Management commentary	8
Accounting policies	9
Income Statement	11
Balance sheet	12
Notes	13

## **ZP General Partner 3 ApS**

---

### **Entity details**

#### **Entity**

ZP General Partner 3 ApS

Sydmarken 11

DK-2860 Søborg

Central Business Registration No. 41023422

Phone: +45 88 77 36 00

Internet: [www.zealandpharma.com](http://www.zealandpharma.com)

E-mail: [info@zealandpharma.com](mailto:info@zealandpharma.com)

#### **Executive Board**

Emmanuel Dulac, President and Chief Executive Officer

Matthew Donald Dallas, Chief Financial Officer

#### **Company auditors**

EY Godkendt Revisionspartnerselskab

Central Business Registration No. 30700228

## ZP General Partner 3 ApS

---

### Statement by Management on the annual report

The Executive Board has today considered and approved the annual report of ZP General Partner 3 ApS for the financial period 9 December 2019 to 31 December 2020.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31 December 2020 and of its financial performance for the financial period 9 December 2019 to 31 December 2020.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Søborg, 30 June 2021

### Executive Board

DocuSigned by:

*Emmanuel Dulac*

665D951DA41543B...

Emmanuel Dulac

President and Chief Executive Officer

DocuSigned by:

*Matthew Dallas*

4E8A30BEF845413...

Matthew Donald Dallas

Chief Financial Officer

## **ZP General Partner 3 ApS**

---

# **Independent auditor's report**

## **To the shareholder of ZP General Partner 3 ApS**

### **Opinion**

We have audited the financial statements of ZP General Partner 3 ApS ("Entity") for the financial year 9 December 2019 – 31 December 2020, which comprise the income statement, balance sheet and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31 December 2020 and of the results of its operations for the financial year 9 December 2019 – 31 December 2020 in accordance with the Danish Financial Statements Act.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### ***Independence***

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

### **Management's responsibilities for the financial statements**

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are

## **ZP General Partner 3 ApS**

---

considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### **Statement on the Management's review**

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

## **ZP General Partner 3 ApS**

---

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 30 June 2021

EY Godkendt Revisionspartnerselskab

CVR no. 30 70 02 28



Christian Schwenn Johansen  
State Authorised  
Public Accountant  
mne33234



Rasmus Bloch Jespersen  
State Authorised  
Public Accountant  
mne35503

## **ZP General Partner 3 ApS**

---

### **Management commentary**

#### **Primary activities**

The objective of the company is to act as General Partner in ZP SPV 3 K/S. There are no other activities in the Company.

#### **Development in activities and finances**

The income statement for 2020 shows a profit of the year of USD 1,824 thousand and the balance sheet at 31 December 2020 shows equity of USD 1,884 thousand.

#### **Events after the balance sheet date**

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.



## **ZP General Partner 3 ApS**

---

### **Accounting policies**

The annual report is presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.

The functional currency for the Company is Danish Kroner. The financial statements are presented in US dollar (USD). The exchange rate at 31 December 2020 was DKK/USD 6.0576.

The financial year 2019/2020 is the initial financial year of the Company. Hence no comparatives are presented in these financial statements.

#### **Foreign currency translation**

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rate at the transaction date and the rate at the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables, payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses. Non-current assets acquired in foreign currency are measured at the exchange rate at the transaction date.

#### **Recognition and measurement**

Assets are recognized in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognized in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is affected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognized in the income statement when earned, whereas costs are recognized by the amounts attributable to this financial year.

## **ZP General Partner 3 ApS**

---

### **Accounting policies**

#### **Income statement**

##### **Revenue**

Revenue comprise fees from acting as General Partner and is recognized in the income statement in the period in which they are incurred.

##### **Administrative expenses**

Administrative expenses comprise expenses relating to administration, accounting, audit, and legal, etc. Administrative expenses are recognized in the income statement in the period in which they are incurred.

##### **Income tax**

Tax for the year, which consists of current tax for the year, is recognized in the income statement by the portion attributable to the profit for the year and recognized directly in equity by the portion attributable to entries directly in equity.

The company participates in a Danish joint taxation arrangement in which Zealand Pharma A/S serves as the administration company. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

#### **Balance sheet**

##### **Receivables**

Receivables are measured at amortized cost usually equaling nominal value less write-downs for bad and doubtful debt.

##### **Cash**

Cash comprise cash in banks.

##### **Other payables**

Other payables are measured at amortized cost which usually corresponds to nominal value.

**ZP General Partner 3 ApS**

---

**Income statement***For the period 9 December 2019 – 31 December*

<i>USD'000</i>	<u>Notes</u>	<u>2019/2020</u>
Revenue		<u>280</u>
<b>Gross Margin</b>		<b>280</b>
Administrative expenses	1	<u>-1</u>
<b>Operating profit/loss</b>		<u><b>279</b></u>
Tax for the year		<u>-61</u>
<b>Profit/loss for the year</b>		<u><b>218</b></u>
<b>Proposed distribution of profit/loss of the year</b>		
Retained earnings		<u>218</u>
		<u><b>218</b></u>

**ZP General Partner 3 ApS**

---

**Balance sheet***At 31 December**USD'000*

<b>Assets</b>	<b>Notes</b>	<b>2020</b>
Intercompany receivables		303
Cash and cash equivalents		<u>10</u>
<b>Total current assets</b>		<b><u>313</u></b>
<b>Total assets</b>		<b><u><u>313</u></u></b>

<b>Equity and liabilities</b>	<b>Notes</b>	<b>2020</b>
Share capital	2,3	10
Retained earnings	3	<u>235</u>
<b>Total equity</b>	3, 4	<b><u>245</u></b>
Intercompany payables		66
Other payables		<u>2</u>
<b>Total short-term liabilities</b>		<b><u>68</u></b>
<b>Total liabilities</b>		<b><u>68</u></b>
<b>Total equity and liabilities</b>		<b><u><u>313</u></u></b>

**ZP General Partner 3 ApS**

---

**Notes****1. Administrative expenses**

There have been no employees during the financial year and there have been no payments or wages or remuneration to the Executive Board.

**2. Share capital**

Share capital consist of 40,000 shares of nominal DKK 1.00 per share. The shares have not been divided into classes.

**3. Equity**

USD'000	<b>Share capital</b>	<b>Retained earnings</b>	<b>Total</b>
Equity at 9 December 2019	10	0	10
Currency translation	0	17	17
Net profit for the period	0	218	218
<b>Equity at 31 December 2020</b>	<b>10</b>	<b>235</b>	<b>245</b>

**4. Ownership**

The company is owned 100% by Zealand Pharma A/S (Central Business Registration No. 20045078).

The consolidated financial statements of Zealand Pharma A/S can be retrieved at the following link:

<https://static1.squarespace.com/static/58983777d1758e28995640b4/t/604a1939ec446c62bceeb6f/1615468866056/Annual+report+for+2020.pdf>

**5. Contingent liabilities**

The company is general partner in ZP SPV 3 K/S. The general partner are direct, personal, unlimited and joint and several liability for all the liabilities and obligations of the Limited Partnership.

The company participates in a Danish joint taxation arrangement in which Zealand Pharma A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the company is therefore liable for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies.